MD-OncoMD-OncoMD-Onco2782-32022782-6171Publishing House ABV Press20210.17650/2782-3202-2025-5-3-94-102THEORETICAL AND DISCUSSIBLE ASPECTS IN ONCOLOGYТЕОРЕТИЧЕСКИЕ И ДИСКУТАБЕЛЬНЫЕ АСПЕКТЫ В ОНКОЛОГИИDendritic cell vaccines for lung cancer: current status and development prospects. Literature reviewДендритно-клеточные вакцины при раке легкого: современное состояние и перспективы развития. Обзор литературыhttps://orcid.org/0000-0002-9616-8996SheikoE. A.ШейкоЕ. А.
Russian Federation

63 14th Line St., Rostov-on-Don 344038

344038 Ростов-на-Дону, 14-я линия, 63

https://orcid.org/0000-0003-3618-6890FrantsiyantsE. M.ФранциянцЕ. М.
Russian Federation

63 14th Line St., Rostov-on-Don 344038

344038 Ростов-на-Дону, 14-я линия, 63

https://orcid.org/0000-0002-2302-8271BandovkinaV. A.БандовкинаВ. А.
Russian Federation

63 14th Line St., Rostov-on-Don 344038

344038 Ростов-на-Дону, 14-я линия, 63

https://orcid.org/0000-0002-4318-7587SurikovaE. I.СуриковаЕ. И.
Russian Federation

63 14th Line St., Rostov-on-Don 344038

344038 Ростов-на-Дону, 14-я линия, 63

https://orcid.org/0000-0003-2943-7655ShikhlyarovaA. I.ШихляроваА. И.
Russian Federation

63 14th Line St., Rostov-on-Don 344038

344038 Ростов-на-Дону, 14-я линия, 63

https://orcid.org/0000-0002-3972-2452KaplievaI. V.КаплиеваИ. В.
Russian Federation

63 14th Line St., Rostov-on-Don 344038

344038 Ростов-на-Дону, 14-я линия, 63

https://orcid.org/0000-0002-0068-0881UshakovaN. D.УшаковаН. Д.
Russian Federation

63 14th Line St., Rostov-on-Don 344038

344038 Ростов-на-Дону, 14-я линия, 63

https://orcid.org/0000-0002-4558-5896FilippovaS. Yu.ФилипповаС. Ю.
Russian Federation

63 14th Line St., Rostov-on-Don 344038

344038 Ростов-на-Дону, 14-я линия, 63

https://orcid.org/0000-0002-7902-7278MezhevovaI. V.МежевоваИ. В.
Russian Federation

63 14th Line St., Rostov-on-Don 344038

344038 Ростов-на-Дону, 14-я линия, 63

https://orcid.org/0000-0003-0640-2994KharagezovD. A.ХарагезовД. А.
Russian Federation

63 14th Line St., Rostov-on-Don 344038

344038 Ростов-на-Дону, 14-я линия, 63

National Medical Research Center of Oncology, Ministry of Health of RussiaФГБУ «Национальный медицинский исследовательский центр онкологии» Минздрава России2109202553941022109202521092025Copyright ©; 2025, ABV-PressCopyright ©; 2025, АБВ-пресс2025ABV-PressАБВ-прессhttps://mdonco.abvpress.ru/jour/about/editorialPolicieshttps://mdonco.abvpress.ru/jour/article/view/202

This paper presents a literature review on the use of dendritic cell vaccines for lung cancer, prepared based on the analysis of sources from domestic and foreign literature presented in electronic databases of scientific medical literature PabMed, eLIBRARY.RU. The analysis included publications characterizing the current capabilities of laboratory, instrumental and molecular genetic methods for obtaining and using dendritic cell vaccines for lung cancer.The aim of the work – to highlight the results of international and domestic studies on the production, screening and use of dendritic cell vaccines, as well as immunotherapy strategies for lung cancer.

Представлен обзор литературы, посвященной использованию дендритно-клеточных вакцин при раке легкого. Обзор подготовлен по результатам анализа отечественных и зарубежных работ, представленных в электронных базах данных научной медицинской литературы PubMed, eLIBRARY. В анализ включали публикации, характеризующие современные возможности лабораторных, инструментальных и молекулярно-генетических методов получения и использования дендритно-клеточных вакцин при раке легкого.Цель работы – осветить результаты международных и отечественных исследований получения, скрининга использования дендритно-клеточных вакцин, а также стратегии иммунотерапии при раке легкого.

lung cancerdendritic celldendritic cell vaccineimmunotherapyрак легкогодендритная клеткадендритно-клеточная вакцинаиммунотерапияBray F., Ferlay J., Soerjomataram I. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68(6):394–424. DOI: 10.3322/caac.21492Siegel R.L., Miller K.D., Jemal A. Cancer statistics 2018. CA Cancer J Clin 2018;68(1):7–30. DOI: 10.3322/caac.21442Abdurakhmanov B.A., Avizova Z.K. Mortality from lung cancer due to delayed treatment: literature review. Onkologiya i Radiolologiya Kazakhstana = Oncology and Radiology of Kazakhstan 2021;2(60): 36–8. (In Russ.). DOI: 10.52532/2521-6414-2021-2-60-36-38Абдурахманов Б.А., Авизова З.К. Смертность от рака легкого из-за задержки лечения: обзор литературы. Онкология и радиология Казахстана 2021;2(60):36–8. DOI: 10.52532/2521-6414-2021-2-60-36-38Larina V.N., Vartanyan E.A., Samorodskaya I.V. Analysis of the structure of mortality from malignant neoplasms in Moscow in 2019, 2020, and 2021. Onkologiya. Zhurnal im. P.A. Hertsena = P.A. Herzen Journal of Oncology 2023;12(4):35–41. (In Russ.). DOI: 10.17116/onkolog20231204135Ларина В.Н., Вартанян Е.А., Самородская И.В. Анализ структуры смертности от злокачественных новообразований в Москве в 2019, 2020, 2021 гг. Онкология. Журнал им. П.А. Герцена 2023;12(4):35–41. DOI: 10.17116/onkolog20231204135Malignant neoplasms in Russia in 2023 (morbidity and mortality). Ed. by A.D. Kaprin, V.V. Starinskiy, A.O. Shaxzadova. Moscow: MNIOI im. P.A. Gercena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2024. 276 p. (In Russ.).Злокачественные новообразования в России в 2023 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2024. 276 с. 5.Borghaei H., Paz-Ares L., Horn L. et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015;373(17):1627–39. DOI: 10.1056/NEJMoa1507643Reck M., Rodríguez-Abreu D., Robinson A.G. et al. Pembrolizumab versus chemotherapy for PD-L1-positive nonsmall-cell lung cancer. N Engl J Med 2016;375(19):1823–33. DOI: 10.1056/NEJMoa1606774Gandhi L., Rodríguez-Abreu D., Gadgeel S. et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 2018;378(22):2078–92. DOI: 10.1056/NEJMoa1801005Brahmer J., Reckamp K.L., Baas P. et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015;373(2):123–35. DOI: 10.1056/NEJMoa1504627Muenst S., Laubli H., Soysal S.D. et al. The immune system and cancer evasion strategies: therapeutic concepts. J Intern Med 2016;279(6):541–62. DOI: 10.1111/joim.12470O’Donnell J.S., Teng M.W.L., Smyth M.J. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat Rev Clin Oncol 2019;16(3):151–67. DOI: 10.1038/s41571-018-0142-8Ruiz-Cordero R., Devine W.P. Targeted therapy and checkpoint immunotherapy in lung cancer. Surg Pathol Clin 2020;13(1):17–33. DOI: 10.1016/j.path.2019.11.002Vermaelen K. Vaccine strategies to improve anti-cancer cellular immune responses. Front Immunol 2019;10:8. DOI: 10.3389/fimmu.2019.00008Kalinski P., Muthuswamy R., Urban J. Dendritic cells in cancer immunotherapy: vaccines and combination immunotherapies. Expert Rev Vaccines 2013;12(3):285–95. DOI: 10.1586/erv.13.22Bol K.F., Schreibelt G., Rabold K. et al. The clinical application of cancer immunotherapy based on naturally circulating dendritic cells. J Immunother Cancer 2019;7(1):109. DOI: 10.1186/s40425-019-0580-6.Gardner A., de Mingo Pulido Á., Ruffell B. Dendritic cells and their role in immunotherapy. Front Immunol 2020;11:924. DOI: 10.3389/fimmu.2020.00924OʼNeill L.A., Kishton R.J., Rathmell J. A guide to immunometabolism for immunologists. Nat Rev Immunol 2016;16(9):553–65. DOI: 10.1038/nri.2016.70Brombacher E.C., Patente T.A., Quik M., Everts B. Characterization of dendritic cell metabolism by flow cytometry. In: Dendritic cells. Methods in molecular biology. Ed. by V. Sisirak. Vol. 2618. NY: Humana, New York, 2023. DOI: 10.1007/978-1-0716-2938-3_16Gardner A., Ruffell B. Dendritic cells and cancer immunity. Trends Immunol 2016;37(12):855–65. DOI: 10.1016/j.it.2016.09.006Veglia F., Gabrilovich D.I. Dendritic cells in cancer: the role revisited. Curr Opin Immunol 2017;45:43–51. DOI: 10.1016/j.coi.2017.01.002Filin I.Y., Kitaeva K.V., Rutland C.S. et al. Recent advances in experimental dendritic cell vaccines for cancer. Front Oncol 2021;11:730824. DOI: 10.3389/fonc.2021.730824Collin M., Bigley V. Human dendritic cell subsets: an update. Immunology 2018;154(1):3–20. DOI: 10.1111/imm.12888Heger L., Hofer T.P., Bigley V. et al. Subsets of CD1c+ DCs: dendritic cell versus monocyte lineage. Front Immunol 2020;11:559166. DOI: 10.3389/fimmu.2020.559166Leader A.M., Grout J.A., Maier B.B. et al. Single-cell analysis of human non-small cell lung cancer lesions refines tumor classification and patient stratification. Cancer Cell 2021;39(12):1594–609.e1512. DOI: 10.1016/j.ccell.2021.10.009Bourdely P., Anselmi G., Vaivode K. et al. Transcriptional and functional analysis of CD1c+ human dendritic cells identifies a CD163+ subset priming CD8+CD103+ T cells. Immunity 2020;53(2):335–52.e338. DOI: 10.1016/j.immuni.2020.06.002Marceaux C., Weeden C.E., Gordon C.L., Asselin-Labat M.L. Holding our breath: the promise of tissue-resident memory T cells in lung cancer. Transl Lung Cancer Res 2021;10(6):2819–29. DOI: 10.21037/tlcr-20-819Stevens D., Ingels J., Van Lint S. et al. Dendritic cell-based immunotherapy in lung cancer. Front Immunol 2021;11:620374. DOI: 10.3389/fimmu.2020.620374Cook P.C., MacDonald A.S. Dendritic cells in lung immunopathology. Semin Immunopathol 2016;38(4):449–60. DOI: 10.1007/s00281-016-0571-3Kim N., Kim H.K., Lee K. et al. Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma. Nat Commun 2020;11(1):2285. DOI: 10.1038/s41467-020-16164-1Sadeghzadeh M., Bornehdeli S., Mohahammadrezakhani H. et al. Dendritic cell therapy in cancer treatment; the state-of-the-art. Life Sci 2020;254:117580. DOI: 10.1016/j.lfs.2020.117580Wang J.B., Huang X., Li F.R. Impaired dendritic cell functions in lung cancer: a review of recent advances and future perspectives. Cancer Commun (Lond) 2019;39(1):43. DOI: 10.1186/s40880-019-0387-3Schneider T., Hoffmann H., Dienemann H. et al. Non-small cell lung cancer induces an immunosuppressive phenotype of dendritic cells in tumor microenvironment by upregulating B7-H3. J Thorac Oncol 2011;6(7):1162–8. DOI: 10.1097/JTO.0b013e31821c421dTopalian S.L., Taube J.M., Pardoll D.M. Neoadjuvant checkpoint blockade for cancer immunotherapy. Science 2020;367(6477):eaax0182. DOI: 10.1126/science.aax0182.Jiang T., Chen X., Zhou W. et al. Immunotherapy with dendritic cells modified with tumor-associated antigen gene demonstrates enhanced antitumor effect against lung cancer. Transl Oncol 2017;10(2):132–41. DOI: 10.1016/j.tranon.2016.12.002Shuo W., Yuntian D., Huan P. et al. Progress in the treatment of non-small cell lung cancer with immune checkpoint inhibitors. Med J Peking Union Medical College Hospital 2023;14(2):409–15.Melero I., Castanon E., Alvarez M. et al. Intratumoural administration and tumour tissue targeting of cancer immunotherapies. Nat Rev Clin Oncol 2021;18(9):558–76. DOI: 10.1038/s41571-021-00507-yTao Li., Kan Zh., Wenyu Ya. et al. Clinical application of immune checkpoint inhibitors CTLA-4 in solid tumors. Med J Peking Union Medical College Hospital 2023;14(3):652–9. DOI: 10.12290/xhyxzz.2022-0617Liyuan D., Yuankai Sh., Xiaohong H. Advances in dynamic monitoring of immune checkpoint inhibitors as the prognostic markers for advanced non-small cell lung cancer. Med J Peking Union Medical College Hospital 2022;13(2):287–95. DOI: 10.12290/xhyxzz.2021-0608Mastelic-Gavillet B., Balint K., Boudousquie C. et al. Personalized dendritic cell vaccines-recent breakthroughs and encouraging clinical results. Front Immunol 2019;10:766. DOI: 10.3389/fimmu.2019.00766Lee K.W., Yam J.W.P., Mao X. Dendritic cell vaccines: a shift from conventional approach to new generations. Cells 2023;12(17):2147. DOI: 10.3390/cells12172147Takahashi H., Shimodaira S., Ogasawara M. et al. Lung adenocarcinoma may be a more susceptive subtype to a dendritic cell-based cancer vaccine than other subtypes of non-small cell lung cancers: a multicenter retrospective analysis. Cancer Immunol Immunother 2016;65(9):1099–111. DOI: 10.1007/s00262-016-1872-zGe C., Li R., Song H. et al. Phase I clinical trial of a novel autologous modified-DC vaccine in patients with resected NSCLC. BMC Cancer 2017;17(1):884. DOI: 10.1186/s12885-017-3859-3Sanchez-Paulete A.R., Cueto F.J., Martinez-Lopez M. et al. Cancer immunotherapy with immunomodulatory anti-CD137 and anti-PD-1 monoclonal antibodies requires BATF3-dependent dendritic cells. Cancer Discov 2016;6(1):71–9. DOI: 10.1158/2159-8290.CD-15-0510Hammerich L., Marron T.U., Upadhyay R. et al. Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination. Nat Med 2019;25(5):814–24. DOI: 10.1038/s41591-019-0410-xIngels J., De Cock L., Stevens D. et al. Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum. Cell Rep Med 2024;5(5):101516. DOI: 10.1016/j.xcrm.2024.101516Huang J., Reckamp K.L. Immunotherapy in advanced non-small cell lung cancer. Semin Respir Crit Care Med 2020;41(3):400–8. DOI: 10.1055/s-0040-1710077Punekar S.R., Shum E., Grello C.M. et al. Immunotherapy in non-small cell lung cancer: past, present, and future directions. Front Oncol 2022;12:877594. DOI: 10.3389/fonc.2022.877594Desai A., Peters S. Immunotherapy-based combinations in metastatic NSCLC. Cancer Treat Rev 2023;116:102545. DOI: 10.1016/j.ctrv.2023.102545Kharagezov D.A., Antonyan A.A., Zlatnik E. et al. The role of tumor stem cells and the immune microenvironment in the pathogenesis of lung cancer: mechanisms of interaction and research prospects. Yuzhno-Rossijskij onkologicheskij zhurnal = South Russian Journal of Cancer 2024;5(4):58–70. (In Russ.). DOI: 10.37748/2686-9039-2024-5-4-7Харагезов Д.А., Антонян А.А., Златник Е.Ю. и др. Роль опухолевых стволовых клеток и иммунного микроокружения в патогенезе рака легкого: механизмы взаимодействия и перспективы исследований. Южно-Российский онкологический журнал 2024;5(4):58–70. DOI: 10.37748/2686-9039-2024-5-4-7De Oliveira J.B., Silva S.B., Fernandes I.L. et al. Dendritic cell-based immunotherapy in non-small cell lung cancer: a comprehensive critical review. Front Immunol 2024; 15:1376704. DOI: 10.3389/fimmu.2024.1376704Laureano R.S., Sprooten J., Vanmeerbeerk I. et al. Trial watch: dendritic cell (DC)-based immunotherapy for cancer. Oncoimmunology 2022;11(1):2096363. DOI: 10.1080/2162402X.2022.2096363Kumar C., Kohli S., Bapsy P.P. et al. Immune modulation by dendritic-cell-based cancer vaccines. J Biosci 2017;42(1):161–73. DOI: 10.1007/s12038-017-9665-x